Find a Clinical Trial

Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

This is a Phase 1, two-part, randomized, double blind, placebo controlled, ascending dose study to evaluate the safety, tolerability, pharmacokinetics of STI-1558 administered orally to healthy volunteers.

Purpose of Study

This is a Phase 1, two-part, randomized, double blind, placebo controlled, single ascending dose (Part 1) and multiple ascending dose (Part 2) study to evaluate the safety, tolerability, pharmacokinetics (PK) of STI-1558 administered orally to healthy volunteers. Part 1 of the study will also incorporate a single-cohort arm to investigate the effect of food on the PK of STI-1558. Dietary status of administration in part 2 (fasted or fed) will be determined by the PK data from Part 1. Part 2 may run in parallel with Part 1, providing that the total daily dose to be administered does not exceed a dose already shown to be safe and well-tolerated in Part 1.

Eligibility

Age:
18 - 45
Sex:
All

Key Inclusion / Exclusion Criteria

Inclusion Criteria:

Body mass index (BMI) is between 18 and 30 kg/m2 (both inclusive), and Body weight between 45 and 100 kg (inclusive)
Generally normal, or abnormal with no clinical significance as judged by the primary investigator based on physical examination, vital signs, electrocardiogram, and clinical laboratory tests
Willing to follow contraception guidelines
Willing and able to comply with study procedures and follow-up visits

Exclusion

Exclusion Criteria:

Difficulty or history of dizziness during venous blood collection or encountering blood or needles
Known or suspected pregnancy, planned pregnancy, a positive pregnancy test at screening or are breastfeeding
A clinically relevant intolerance or allergy to drugs, or are known or suspected to have hypersensitivity to any ingredient in STI-1558 capsules
Received an experimental agent within 1 month or 5 times half-life (whichever is longer) prior to the first dose of study drug
Has a history of gastrointestinal, liver or kidney disease, or other condition that may exclude the subject as determined by the investigator
Has a medical history of significant diseases as determined by the investigator
Has a history of febrile illness within 14 days prior to the first dose of study drug
Has values above the upper limit of normal alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase at screening or Day -1 and judged to be clinically significant by the investigator
Prolonged QTcF interval
Has had major surgery within 3 months prior to the first dose of study drug or plans to undergo surgery during the study
Any marketed medication within 14 days or 5 times the half-life, whichever is longer, prior to the first dose of study drug
Vaccinated within 14 days prior to the first dose of study drug or plans to be vaccinated during the study
Is unwilling to abstain from quinine containing products or grapefruit during the study
Use of BCRP substrates within 7 days prior to the first dose of study drug
A known history of drug abuse within 2 years before screening or positive drug abuse test at screening
Blood donation or blood loss > 400 mL within 3 months prior to screening
Weekly alcohol consumption of more than 14 units of alcohol in any week within the past 3 months prior to screening, or intake of alcohol within 48 hours prior to first dose of study drug, or cannot abstain from alcohol during the study, or positive breath alcohol test at screening or Day -1
Significant smoking history within 3 months before screening
Excessive drinking of caffeinated beverages within 3 months before screening, or intake of caffeine-containing products within 48 hours prior to the first dose of study drug
Have human immunodeficiency virus (HIV) infection, human T-cell leukemia virus type 1 (HTLV1) infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or are at risk for HBV reactivation (at risk for HBV reactivation is defined as being HBs antigen positive, or anti-HBc-antibody positive), or are positive for HBV deoxyribonucleic acid (DNA). HCV ribonucleic acid (RNA) must be undetectable by laboratory test
Positive SARS-CoV-2 test on Day -1
Subjects who are judged as not eligible to participate in this study as determined by the investigator or designee

Conditions:


Notice: Undefined variable: tags_list in /nas/content/live/jshi/wp-content/themes/sorrento/functions.php on line 630

Warning: Invalid argument supplied for foreach() in /nas/content/live/jshi/wp-content/plugins/clinicaltrials/clinicaltrials.php on line 312

Status:

Not yet recruiting

Phase:

Phase 1

Study ID

NCT05364840

Read Detailed Summary

Start Date / End Date:

01/05/2022 -

Enrollment:

58

Full Details:

https://clinicaltrials.gov/ct2/show/NCT05364840

SELECT post_id, meta_key, meta_value FROM wp_postmeta WHERE post_id IN (5355) ORDER BY meta_id ASC /* From [sorrentotherapeutics.com/study/study-to-assess-the-safety-tolerability-and-pharmacokinetics-of-sti-1558-in-healthy-volunteers/] in [/nas/content/live/jshi/wp-content/themes/sorrento/single-study.php:255] */

1 Study Locations

Australia

Scientia Clinical Research Ltd
Randwick, New South Wales, 2031
Australia


email: pavithra.jayatilake@scientiaclinicalresearch.com.au


Study Locations Map: